Abstracts tagged "Behcet’s syndrome"

Abstract Number: 3037 • 2015 ACR/ARHP Annual Meeting
Serum Anti-Lysozyme Is Associated with Disease Activity of Behcet’s Disease
Jin Su Park¹, Mi-il Kang², You Jung Ha³, Yong-Beom Park⁴, Soo-Kon Lee⁵ and Sang-Won Lee⁶, ¹Department of Internal Medicine, NHIS Ilsan Hospital, Goyang-si Gyeounggi-do, South Korea, ²Department of Internal Medicine, Dankook University Hospital, Cheonan-si Chungcheongnam-do, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁴Yonsei University College of Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul, South Korea, ⁵Internal Medicine, Yonsei Univ College of Med, Seoul, South Korea, ⁶Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: To investigate the association between autoantibodies against non- myeloperoxidase (MPO) neutrophil granule antigens and activity of Behcet’s disease (BD). Methods: We consecutively enrolled 51…
Abstract Number: 3038 • 2015 ACR/ARHP Annual Meeting
Serum CXCL8, 10 and 12 Are Increased in Patients with Behcet’s Disease and CXCL10 Levels Are Correlated with Number of Erythema Nodosum
Sang Jin Lee^1,2, Hyun Jung Yoo³, Hyun Mi Kwon⁴, Jin Young Moon⁴, Jin Kyun Park⁵, Eun Young Lee⁵, Eun Bong Lee⁴ and Yeong Wook Song⁵, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea, ³Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Parmarcy, Seoul National University, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: Chemokines are multifunctional mediators that control leukocyte recruitment into the inflammatory sites and enhance immune responses. It remains to be investigated which chemokines are…
Abstract Number: 3039 • 2015 ACR/ARHP Annual Meeting
Possible Contribution of HLA-A0207, B5201 and IL-23 Receptor Polymorphism in Ocular Behçet Disease
Toshikatsu Kaburaki¹, Shinji Harihara², Rie Tanaka³, Hiromasa Sawamura⁴, Ai Nishi⁴, Atsushi Hatamochi⁵, Jun Shimizu⁶, Masumi Takeuchi⁷, Shoji Kuwata⁸, Hidetoshi Kawashima⁹ and Fujio Takeuchi¹⁰, ¹Ophthalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Division of Anthropology, Department of Biological Science, The University of Tokyo Graduate School of Science, Tokyo, Japan, ³Department of Ophtalmology, The University of Tokyo Graduate School of Medicine,, Tokyo, Japan, ⁴Department of Ophtalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁵Department of Dermatology, Dokkyo Medical University, Tochigi, Japan, ⁶Department of Neurology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁷Teikyo University Support Center for Women Physicians and Researchers, Teikyo University School of Medicine, Tokyo, Japan, ⁸Third Department of Internal Medicine, Teikyo University Chiba Medical Center, Teikyo University School of Medicine, Chiba, Japan, ⁹Department of Ophthalmology, Jichi Medical University, Tochigi, Japan, ¹⁰Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Behçet's disease (BD) is known to be associated with HLA-B*51:01 and HLA- A*26:01 in many different ethnic groups. Recently, HLA-A*02:07, IL-10 and IL23R-IL12RB polymorphisms…
Abstract Number: 3040 • 2015 ACR/ARHP Annual Meeting
Predictive Factors of Long-Term Clinical Outcome in Patients with Ocular Involvement Secondary to Behcet’s Syndrome
Rosaria Talarico¹, Michele Figus², Anna d'Ascanio¹, Rossella Neri¹, Chiara Baldini¹, Chiara Tani³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ²Department of Surgical, Medical, Molecular Pathology and Emergency, University of Pisa, Pisa, Italy, ³University of Pisa, Pisa, Italy
Background/Purpose: Behçet's syndrome (BS) is a multisystemic, chronic relapsing inflammatory disease classified among the vasculitis. Eye involvement represent one of the most serious manifestation of…
Abstract Number: 3041 • 2015 ACR/ARHP Annual Meeting
Long Term Biological Therapy in Uveitis Refractory Due to Behçet’s Disease. Multicenter Study of 165 Patients.
Montserrat Santos-Gómez¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Emma Beltran², Juan Sánchez Bursón Sr.³, Marina Mesquida⁴, Alfredo Adan⁴, M. Victoria Hernández⁵, F.Javier López-Longo⁶, Marisa Hernandez Grafella⁷, Elia Valls Pascual⁸, Lucía Martinez-Costa⁹, Agusti Sellas-Fernandez¹⁰, Miguel Cordero¹¹, Manuel Díaz-Llopis¹², Roberto Gallego¹³, Jose L. García Serrano¹⁴, JL Callejas Rubio¹⁵, Norberto Ortego-Centeno¹⁶, Jose M Herreras¹⁷, Alejandro Fonollosa¹⁸, Angel M. Garcia-Aparicio¹⁹, Olga Maiz Alonso²⁰, Ana Blanco²¹, Ignacio Torre²², Cruz Fernández- Espartero²³, Vega Jovani²⁴, Diana Peiteado²⁵, David Diaz Valle²⁶, Esperanza Pato²⁶, Juan Cruz²⁷, Carlos Férnandez Cid²⁸, Elena Aurrecoechea²⁹, Miriam García-Arias³⁰, Miguel Angel Caracuel-Ruiz³¹, Carlos Alberto Montilla Morales³², Antonio Atanes-Sandoval³³, Félix Francisco³⁴, Santos Insua³⁵, Senen González-Suárez³⁶, Amalia Sánchez-Andrade³⁷, Fernando Gamero³⁸, Luis Francisco Linares³⁹, Fredeswinda Romero⁴⁰, A. Javier García-González⁴¹, Raquel Almodóvar González⁴², Enrique Minguez⁴³, Carmen Carrasco Cubero⁴⁴, Alejandro Olivé⁴⁵, Julio Vázquez⁴⁶, Oscar Ruiz Moreno⁴⁷, Fernando Jiménez-Zorzo⁴⁸, Javier Manero⁴⁸, Santiago MuÑoz Fernandez⁴⁹, Cristina Fernández-Carballido⁵⁰, Esteban Rubio Romero⁵¹, Fred Antón Pagés⁵², Javier Toyos-Saenz de Miera⁵³, Myriam Gandía⁵⁴, Carmen Gonzalez-Vela⁵⁵, Enrique Raya⁵⁶, Natalia Palmou¹, Leyre Riancho-Zarrabeitia¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ³Rheumatology, Hospital de Valme., Sevilla, Spain, ⁴Ophthalmology, Hospital Clinic, Barcelona, Spain, ⁵Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Ophthalmology., Hospital General Universitario de Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ⁹Ophthalmology, Hospital Universitario Dr Peset, Valencia, Spain, ¹⁰Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ¹¹Ophthalmology, Hospital de León, León, Spain, ¹²Hospital Universitario La Fe, Valencia, Spain, ¹³Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, ¹⁴Ophthalmology, Hospital Universitario San Cecilio, Granada, Spain, ¹⁵Hospital Universitario San Cecilio, Granada, Spain, ¹⁶Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ¹⁷Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ¹⁸Ophtalmology, Hospital de Cruces, Bilbao, Spain, ¹⁹Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ²⁰Rheumatology, Donostia University Hospital, Donostia, Spain, ²¹Ophthalmology, Donostia University Hospital, Donostia, Spain, ²²Rheumatology, Hospital de Basurto, Bilbao, Spain, ²³Rheumatology, Hospital La Zarzuela, Madrid, Spain, ²⁴Rheumatology, Hospital General de Alicante, Alicante, Spain, ²⁵Rheumatology, Hospital La Paz, Madrid, Spain, ²⁶Hospital Clínico San Carlos, Madrid, Spain, ²⁷Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, ²⁸Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, ²⁹Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ³⁰Rheumatology, Hospital La Princesa, Madrid, Spain, ³¹Plaza Cruz Roja, 1, Hospital Reina Sofia, Córdoba, Spain, ³²Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ³³Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ³⁴Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³⁵Rheumatology, Hospital Universitario Santiago de Compostela, La Coruña, Spain, ³⁶Rheumatology, Hospital de Cabueñes, Gijón, Spain, ³⁷Hospital Lucus Augusti, Lugo, Spain, ³⁸Rheumatology, Hospital San Pedro Alcántara, Cáceres, Spain, ³⁹Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ⁴⁰Section for Autoimmune Diseases, Rheumatology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ⁴¹Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴²Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁴³Ophthalmology., Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴⁴Rheumatology, Hospital de Mérida, Mérida, Spain, ⁴⁵Hospital Germans Trias i Pujol, Badalona, Spain, ⁴⁶Rheumatology., Hospital de Ferrol, La Coruña, Spain, ⁴⁷Ophthalmology and Rheumatology., Hospital Miguel Servet, Zaragoza, Spain, ⁴⁸Ophthalmology and Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴⁹Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ⁵⁰Rheumatology, Hospital General Universitario de Elda, Elda (Alicante), Spain, ⁵¹Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵²Rheumatology, Hospital de Palencia, Palencia, Spain, ⁵³Rheumatology, Hospital Virgen de la Macarena, Seville, Spain, ⁵⁴Department of Autoimmune Diseases, IDIBAPS, Hospital Clínic, Barcelona, Spain, ⁵⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁵⁶Rheumatology, Hospital Universitario San Cecilio, Granada, Spain
Background/Purpose: Conventional management of uveitis due to Behçet’s disease (UBD) consists on conventional immunosuppressive drugs. However, UBD is often refractory requiring more intensive therapy.Our aim was…
Abstract Number: 3042 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Uveitis Associated with Behçet’s Disease. Multicenter Study of 7 Patients.
Montserrat Santos-Gómez¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Emma Beltran², Antonio Atanes-Sandoval³, Enar Pons⁴, Javier Loricera¹, Carmen Gonzalez-Vela⁵, Leyre Riancho-Zarrabeitia¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ³Rheumatology, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain, ⁴Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Treatment recommended in severe and/or refractory uveitis of Behçet disease is anti-TNF-α therapy, usually infliximab (IFX) or adalimumab (ADA) (Levy-Clarke et al Ophthalmology 2014;121:785-796).…
Abstract Number: 3043 • 2015 ACR/ARHP Annual Meeting
IL-17 Expression By Lymphocytes Is Higher in Behcet’s Disease Compared to Takayasu Arteritis
Ali Ugur Unal¹, Rabia Deniz², Aysin Tulunay Virlan³, Filiz Ture Ozdemir³, Imren Aydin Tatli³, Gulsen Ozen¹, Fatma Alibaz-Oner⁴, Gonca Mumcu⁵, Tulin Ergun⁶ and Haner Direskeneli¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁴Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁵Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁶Dermatology, Marmara University Faculty of Medicine, Dermatology, Istanbul, Turkey
Background/Purpose: Interleukin-17 (IL-17) has been associated with the pathogenesis of various inflammatory diseases. The aim of our study was to investigate the expression of Th17-related…
Abstract Number: 3044 • 2015 ACR/ARHP Annual Meeting
Microparticles (MPs) Derived from Cell Plasma Membranes Are Increased in Behcet’s Syndrome (BS) and a Low Ratio of Tissue Factor Pathway Inhibitor Positive Mps to Tissue Factor Positive Mps (TFPI/TF) Is Associated with Thrombosis
Emon Khan¹, Nicola Ambrose¹, Miles Stanford², Michael A. Laffan³ and Dorian O. Haskard⁴, ¹Department of Vascular Sciences, National Heart and Lung Institute, Imperial College, London, United Kingdom, ²Ophthalmology, Guy's and St. Thomas' Hospital, London, United Kingdom, ³Department of Haemostasis and Thrombosis, Imperial College, London, United Kingdom, ⁴Rheumatology, Imperial College, London, United Kingdom
Background/Purpose: Thrombosis occurs in around 20% of Behçet's Syndrome (BS) patients and causes substantial morbidity. There is a clear need for better biomarkers of thrombotic…
Abstract Number: 2758 • 2014 ACR/ARHP Annual Meeting
Predictive Factors for the Response to Infliximab Therapy in Patients with Behçet’s Disease
Salvatore D'Angelo¹, Pietro Leccese¹, Angela Padula¹, Angelo Nigro¹, Michele Gilio², Antonio Carriero¹, Carlo Palazzi¹ and Ignazio Olivieri¹, ¹Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, ²San Carlo Hospital, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy
Background/Purpose: To identify the clinical factors predicting a good clinical response to Infliximab (IFX) therapy after 12 months in patients with Behçet’s disease (BD) refractory…
Abstract Number: 1212 • 2014 ACR/ARHP Annual Meeting
Behcets Disease in Females Due to Mutation in NEMO, the NF-Kb Essential Modulator
Alex Wessel¹, Spiros Vonortas², Jevgenia Zilberman-Rudenko³, Richard Siegel⁴ and Eric Hanson⁵, ¹5814 Beech Ave, NIH, Bethseda, MD, ²NIH, NIAMS, Bethesda, MD, ³Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAMS, NIH, Bethesda, MD, ⁵National Institute of Health, Bethesda, MD
Background/Purpose: Behçet's disease (BD) is a chronic multi-system inflammatory disorder associated clinically with oral and genital ulceration, uveitis, erythema nodosum, and other inflammatory disease. The…
Abstract Number: 2760 • 2014 ACR/ARHP Annual Meeting
Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
Yasin Keskin¹, Emire Seyahi², Cagri Poyraz³, Serdal Ugurlu¹, Yilmaz Ozyazgan⁴ and Hasan Yazici⁵, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Psychiatry, Cerrahpasa Medical Faculty, University Of Istanbul, Istanbul, Istanbul, Turkey, ⁴Department of Ophthalmology, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Interferon (IFN) is an effective immune-modulatory agent in the medical management of eye disease of Behçet’s syndrome (BS). The agent is frequently associated with…
Abstract Number: 2762 • 2014 ACR/ARHP Annual Meeting
Atrophy of Hippocampal Region in Chronic Progressive Neuro-Behçet’s Disease
Hirotoshi Kikuchi¹, Kurumi Asako¹, Maki Takayama¹, Yoshitaka Kimura¹, Akiko Okamoto¹, Toshihiro Nanki^1,2, Hajime Kono¹ and Shunsei Hirohata³, ¹Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Department of Clinical Research Medicine, Teikyo University, Tokyo, Japan, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Central nervous system involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB)…
Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Shunsei Hirohata¹, Hirotoshi Kikuchi², Tetsuji Sawada³, Hiroko Nagafuchi⁴, Msataka Kuwana⁵, Mitsuhiro Takeno⁶ and Yoshiaki Ishigatsubo⁷, ¹Int Med/Rheumatol & Infec Dis, Kitasato Univ School of Med, Kanagawa, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Internal Medicine 3, Tokyo Medical University, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁵Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan, ⁷Int Med & Clin Immunology, Yokohama City Grad Schl of Med, Yokohama, Japan
Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…
Abstract Number: 2744 • 2014 ACR/ARHP Annual Meeting
Mi-RNA Profile of Active Vascular BEHÇET’S Patients
Ahmet Mesut Onat¹, Ozan Gerenli², Bunyamin Kisacik¹, Mustafa Ulasli³, Gezmis Kimyon⁴, Yavuz Pehlivan⁵ and Serdar Oztuzcu⁶, ¹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ²Rheumatology, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey, ³Genetics, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey, ⁴Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁵Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ⁶Genetcs, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey
Background/Purpose Behçet’s Disease (BD) is a systemic vasculitis that predominantly presented with oral aphtous ulcers and additionally at least two of the following findings like…
Abstract Number: 2745 • 2014 ACR/ARHP Annual Meeting
Plasma of Patients with Active Behçet´s Disease (BD) Increases Neutrophil Extracellular Trap Formation, Oxidative Metabolism and NADPH-Oxidase Expression in Normal and BD Neutrophils, and Carries Several Neutrophil Stimulating Factors
Sandro F. Perazzio^1,2, Paulo Vitor Soeiro Pereira³, Alexandre W. S. de Souza¹, Antonio Condino-Neto³ and Luis Eduardo C. Andrade^2,4, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Fleury Medicine and Health, Sao Paulo, Brazil, ³Immunology, ICB IV - Universidade de São Paulo, São Paulo, Brazil, ⁴Fleury Laboratories, Sao Paulo, Brazil
Background/Purpose Plasma factors seem to play a role in Behçet’s disease (BD) pathogenesis, especially by increasing phagocyte oxidative profile. No data exists regarding neutrophil extracellular…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.